Mandric 2008.

Methods	CCT comparing enalapril to placebo
Participants	30 survivors of paediatric haematological malignancies, aged between 6 and 14 years and treated with doxorubicin. All participants had at least 1 cardiac abnormality identified at any time after anthracyclines exposure. Enalapril group: 10 children, mean age at diagnosis 6 years, mean or median follow‐up 16 months Placebo group: 20 children. Mean age and follow‐up not mentioned. Both groups had been treated with similar doses of anthracyclines. No further participant characteristics were provided. Duration of follow‐up was unclear
Interventions	Enalapril (dose range between 0.2 and 0.5 mg/kg/day) Placebo (not further specified)
Outcomes	Cardiac evaluation (including echocardiography) at baseline and at 3, 6, 12, 16 months after initiation of enalapril/placebo therapy. In the enalapril group, progressive improvement in LV dimensions (end‐systolic and end‐diastolic), fractional shortening, LV mass, LV per cent posterior wall thickening, interventricular per cent septal thickening, and Tei index was found. In the placebo group, the same echocardiographic parameters were constant or worsened in the course of follow‐up (not further specified)
Notes	This study has not been published in full text, but was presented at the SIOP conference 2008 (abstract L.030). It seems that children were not randomised. Completeness of follow‐up was not mentioned